Isocitrate dehydrogenase 1: What it means to the neurosurgeon

Journal of Neurosurgery

Volumn 118, Issue 6, 2013, Pages 1176-1180

  Hodges, Tiffany R ^a,b   Choi, Bryan D ^a,b   Bigner, Darell D ^b   Yan, Hai ^b   Sampson, John H ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Genetics; Glioma; Isocitrate dehydrogenase 1; Mutation; Oncology

Indexed keywords

DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; ISOCITRATE DEHYDROGENASE 1;

ACUTE GRANULOCYTIC LEUKEMIA; ASTROCYTOMA; GAIN OF FUNCTION MUTATION; GENETIC SCREENING; GLIOBLASTOMA; GLIOMA; HUMAN; NEUROECTODERM TUMOR; NEUROSURGEON; OLIGODENDROGLIOMA; PARAGANGLIOMA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

BRAIN NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; GENOTYPE; GLIOBLASTOMA; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; PROGNOSIS;

EID: 84878684515     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2013.3.JNS122282     Document Type: Review

References (33)

1. Alderton GK: Genetics: IDH mosaicism in enchondromatosis syndromes. Nat Rev Cancer 12:6, 2012
2. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al: IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224:334-343, 2011
3. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al: Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 4:116ra4, 2012
4. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602, 2008
5. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al: IDH1 mutations at residue p. R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30:7-11, 2009
6. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, et al: Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 51:73-78, 2010
7. Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, et al: Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 121:241-252, 2011
8. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, et al: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245-254, 2010
9. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al: 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18:624-629, 2012
10. Christensen BC, Smith AA, Zheng SC, Koestler DC, Houseman EA, Marsit CJ, et al: DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 103:143-153, 2011
11. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744, 2009
12. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, et al: IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73:1792-1795, 2009
13. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, et al: Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med 4:116ra5, 2012
14. Gaal J, Burnichon N, Korpershoek E, Roncelin I, Bertherat J, Plouin PF, et al: Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 95:1274-1278, 2010
15. Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, Dinjens W, et al: Segregation of non-p. R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat 31:E1186-E1199, 2010
16. Hayden JT, Frühwald MC, Hasselblatt M, Ellison DW, Bailey S, Clifford SC: Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. Cell Cycle 8:1806-1807, 2009
17. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, et al: Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget 3: 709-722, 2012
18. Jin G, Pirozzi CJ, Chen LH, Lopez GY, Duncan CG, Feng J, et al: Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget 3:774-782, 2012
19. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, et al: Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125:353-355, 2009
20. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD: A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 390:547-551, 2009
21. Lee SM, Koh HJ, Park DC, Song BJ, Huh TL, Park JW: Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med 32:1185-1196, 2002 (Pubitemid 34603355)
22. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al: IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474-478, 2012
23. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066, 2009
24. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-522, 2010
25. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008
26. Reitman ZJ, Choi BD, Spasojevic I, Bigner DD, Sampson JH, Yan H: Enzyme redesign guided by cancer-derived IDH1 mutations. Nat Chem Biol 8:887-889, 2012
27. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27: 4150-4154, 2009
28. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, et al: Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70: 8981-8987, 2010
29. Song Tao Q, Lei Y, Si G, Yan Qing D, Hui Xia H, Xue Lin Z, et al: IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103: 269-273, 2012
30. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, et al: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597-1604, 2010
31. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-1033, 2009
32. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009
33. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al: Gliomaderived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324:261-265, 2009